Patient Immunotherapy Summit: Breast Cancer Brief

Dr. Sarah Sammons, as the Associate Director of the Metastatic Breast Cancer Program at the Dana-Farber Cancer Institute, plays a crucial role in advancing the understanding and treatment of metastatic breast cancer. Her leadership in this specialized program reflects her dedication to addressing the unique challenges faced by individuals with advanced-stage breast cancer. Dr. Sammons brings a wealth of expertise to the forefront, contributing to the development of comprehensive and patient-centric care strategies. Through her work, she strives to improve outcomes for those navigating the complexities of metastatic breast cancer, emphasizing a holistic approach that considers both the medical and emotional aspects of the disease. Dr. Sammons' commitment to the field positions her as a valuable resource and advocate for individuals and families affected by metastatic breast cancer.
Established in 1953, the Cancer Research Institute (CRI) is a 501(c)(3) nonprofit organization dedicated to harnessing our immune system’s power to control and potentially cure all cancers. Our mission: Save more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. To accomplish this, we rely on donor support and collaborative partnerships to fund and carry out the most innovative clinical and laboratory research around the world, support the next generation of the field’s leaders, and serve as the trusted source of information on immunotherapy for cancer patients and their caregivers. www.cancerresearch.org
Cancer Research Institute is a registered 501(c)(3) nonprofit under EIN 13-1837442. Donations are tax-deductible to the fullest extent allowable under the law.